 Currently there are four other NNRTIs undergoing clinical development, IDX899, RDEA-428 and lersivirine (table 2).Rilpivirine is a DAPY compound like etravirine and was discovered when further optimization within this family of NNRTIs was conducted.The resistance profile and the genetic barrier to the development of resistance is comparable to etravirine "in vitro".